CLYM Climb Bio, Inc.

Price Chart

Executive Summary

The SEC declared effective Climb Bio's S-3 registration statement (File No. 333-296346) on June 9, 2026. This shelf registration covers the resale of 11,587,000 shares by selling stockholders, including shares from a prior private placement that raised ~$110M. The company receives no proceeds from these resales, but the effectiveness removes a key overhang and allows selling stockholders to trade freely.

Actionable Insight

Key Facts

• Effectiveness date: June 9, 2026
• Registration covers 11,587,000 shares (9,481,000 outstanding + 2,106,000 pre-funded warrant shares) for resale by selling stockholders
• Shares originated from a private placement on April 27, 2026 that raised ~$110M in gross proceeds
• Company will not receive any proceeds from the resale of shares under this prospectus
• This is a routine resale registration to fulfill contractual registration rights obligations, not a new capital raise

Financial Impact

No new capital raised; potential selling pressure from up to 11.6M shares being registered for resale, but the private placement was already disclosed and priced

Risk Factors

• Potential near-term selling pressure as registered shares become freely tradable
• No new capital raised — company remains dependent on existing cash runway from the April private placement

Market Snapshot

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

US Market Status